Ulipristal Acetate for Use in Early Pregnancy Loss

Phase 2 Completed 3 enrolled University of North Carolina, Chapel Hill North Carolina Translational and Clinical Sciences Institute · collab

NaSingle-groupOpen-labelTreatment

Summary

The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management of early pregnancy loss. Patients will be followed to assess effective treatment of early pregnancy loss, additional interventions needed, side effects, adverse events and patient acceptability.

Timeline

Start: 2022-05-11
Primary completion: 2023-01-03
Completion: 2023-04-30

Publications

Hagey JM, Tang JH, Morse JE, Bryant AG. Ulipristal acetate for use in medical management of early pregnancy loss: a pilot feasibility study. BMC Pregnancy Childbirth. 2026 Jul 2. doi: 10.1186/s12884-026-09485-4. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Misoprostol	Other / unclassified	800 ug	Other
Subject	Ulipristal Acetate	Unknown	90 mg	Oral

Ulipristal Acetate for Use in Early Pregnancy Loss

Summary

Timeline

Publications

Drugs

Indications